SAFETY DATA SHEETS

This SDS packet was issued with item:

078949260

N/A

SAFETY DATA SHEET



Cisplatin

Section 1. Identification

GHS product identifier

: Cisplatin

Product code

: Not available.

Other means of identification

: Not available.

Product type

: Regulated prescription drug.

Container information

: 50 mL glass vial & 100 mL glass vial.

Relevant identified uses of the substance or mixture and uses advised against

Identified uses

: Cisplatin Injection is indicated as therapy to be employed as follows:

<u>Metastatic Testicular Tumors</u> In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already

received appropriate surgical and/or radiotherapeutic procedures.

Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin Injection and cyclophosphamide. Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin

Injection therapy.

<u>Advanced Bladder Cancer</u> Cisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments.

such as surgery and/or radiotherapy.

Manufacturer

: Hikma Farmacêutica (Portugal) S.A

Estrada do Rio da Mó, 8, 8A e 8B – Fervença, Portugal

Tel: + 351 21 960 84 10 Fax: +351 21 961 51 02 Email: agageiro@hikma.com

Supplier's details

: Hikma Pharmaceuticals USA Inc. 246 Industrial Way West Eatontown

New Jersey (NJ) 07724

Emergency telephone number (with hours of operation) : CHEMTREC, U.S.: 1-800-424-9300

International: +1-703-527-3887

24/7

Section 2. Hazards identification

OSHA/HCS status

: This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200).

Classification of the substance or mixture

: CARCINOGENICITY - Category 1B

GHS label elements



Section 2. Hazards identification

Hazard pictograms

Signal word : Danger

Hazard statements : H350 - May cause cancer.

This is a pharmaceutical product designed to be prescribed by a licensed health care professional. Should any person while using this product observe any adverse health effects, they should seek medical treatment.

Precautionary statements

Prevention: P201 - Obtain special instructions before use.

P202 - Do not handle until all safety precautions have been read and understood. P280 - Wear protective gloves. Wear eye or face protection. Wear protective clothing.

Response : P308 + P313 - IF exposed or concerned: Get medical attention.

Storage : P405 - Store locked up.

Disposal : P501 - Dispose of contents and container in accordance with all local, regional, national

and international regulations.

Hazards not otherwise

classified

: None known.

Section 3. Composition/information on ingredients

Substance/mixture

: Mixture

Other means of identification

: Not available.

Ingredient name	%	CAS number
Deuterium oxide Sodium chloride Cisplatin Hydrochloric acid Sodium hydroxide	80 - 100 0.1 - 1 0.01 - 0.1 0.01 - 0.1 0.01 - 0.1	7789-20-0 7647-14-5 15663-27-1 7647-01-0 1310-73-2
Active pharmaceutical ingredient	%	CAS number
Cisplatin	0.01 - 0.1	15663-27-1

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in this section.

Occupational exposure limits, if available, are listed in Section 8.

See Package Insert for further information.

Section 4. First aid measures

<u>Description of necessary first aid measures</u>

Eye contact

: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 20 minutes. Get medical attention.



Section 4. First aid measures

Inhalation

: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Skin contact

: Flush contaminated skin with plenty of water. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 20 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse.

Ingestion

: Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Most important symptoms/effects, acute and delayed

Potential acute health effects

Eye contact
 Inhalation
 No known significant effects or critical hazards.
 Skin contact
 Ingestion
 No known significant effects or critical hazards.
 No known significant effects or critical hazards.
 No known significant effects or critical hazards.

Over-exposure signs/symptoms

Eye contact
 Inhalation
 No known significant effects or critical hazards.
 Skin contact
 Ingestion
 No known significant effects or critical hazards.
 No known significant effects or critical hazards.
 No known significant effects or critical hazards.

Indication of immediate medical attention and special treatment needed, if necessary

Notes to physician

: Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.

Specific treatments

: No specific treatment.

Protection of first-aiders

: No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

See toxicological information (Section 11)



Section 5. Fire-fighting measures

Extinguishing media

Suitable extinguishing

media

Unsuitable extinguishing media

: Use an extinguishing agent suitable for the surrounding fire.

: None known.

Specific hazards arising from the chemical

Hazardous thermal decomposition products

: No specific fire or explosion hazard.

: No specific data.

Special protective actions for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters

: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

For emergency responders

: If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

Environmental precautions

: Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

Methods and materials for containment and cleaning up

Spill

: Stop leak if without risk. Move containers from spill area. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.



Section 7. Handling and storage

Precautions for safe handling

Protective measures

Put on appropriate personal protective equipment (see Section 8). Avoid exposure - obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapor or mist. If during normal use the material presents a respiratory hazard, use only with adequate ventilation or wear appropriate respirator. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.

Advice on general occupational hygiene

: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. See also Section 8 for additional information on hygiene measures.

Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Section 8. Exposure controls/personal protection

Control parameters

Occupational exposure limits

Ingredient name	Exposure limits
Cisplatin	None.

Appropriate engineering controls

: If user operations generate dust, fumes, gas, vapor or mist, use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits.

Environmental exposure controls

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation.

Individual protection measures

Hygiene measures

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period.

Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection Hand protection

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.



Section 8. Exposure controls/personal protection

Body protection

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Section 9. Physical and chemical properties

Appearance

Physical state : Liquid. [Clear solution.] Color : Colorless to yellow/orange.

Odor Not available. : Not available. **Odor threshold** Hq : 3.8 to 4.2 **Melting point** : Not available. Not available. **Boiling point** Not available. Flash point : Not available. **Evaporation rate** Flammability (solid, gas) Not available.

Lower and upper explosive

(flammable) limits

: Not available.

: Not available. Vapor pressure Vapor density Not available. : Not available. Relative density **Solubility** : Not available. Partition coefficient: n-: Not available.

octanol/water

Auto-ignition temperature : Not applicable. : Not available. **Decomposition temperature Viscosity** Not available. Flow time (ISO 2431) : Not available.

Section 10. Stability and reactivity

Reactivity No specific test data related to reactivity available for this product or its ingredients.

Chemical stability : The product is stable.

Possibility of hazardous reactions

: Under normal conditions of storage and use, hazardous reactions will not occur.

Conditions to avoid : No specific data.

Incompatible materials : Reactive or incompatible with the following materials: oxidizing materials.



Section 10. Stability and reactivity

Hazardous decomposition products

 Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

Information on toxicological effects

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
Cisplatin	LD50 Oral	Rat	20 mg/kg	-

Irritation/Corrosion

There is no data available.

Sensitization

There is no data available.

Mutagenicity

There is no data available.

Carcinogenicity

Classification

Product/ingredient name	OSHA	IARC	NTP
Cisplatin	-	2A	Reasonably anticipated to be a human carcinogen.

Reproductive toxicity

There is no data available.

Teratogenicity

There is no data available.

Specific target organ toxicity (single exposure)

There is no data available.

Specific target organ toxicity (repeated exposure)

There is no data available.

Aspiration hazard

There is no data available.

Information on the likely routes of exposure

: Dermal contact. Eye contact. Inhalation. Ingestion.

Potential acute health effects

Eye contact
 Inhalation
 No known significant effects or critical hazards.
 Skin contact
 No known significant effects or critical hazards.
 Ingestion
 No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact
 Inhalation
 No known significant effects or critical hazards.
 Skin contact
 Ingestion
 No known significant effects or critical hazards.
 No known significant effects or critical hazards.



Section 11. Toxicological information

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure

Potential immediate

effects

: No known significant effects or critical hazards.

: No known significant effects or critical hazards.

Long term exposure

Potential immediate

Potential delayed effects

effects

: No known significant effects or critical hazards.

Potential delayed effects : No known significant effects or critical hazards.

Potential chronic health effects

General : No known significant effects or critical hazards.

: May cause cancer. Risk of cancer depends on duration and level of exposure. Carcinogenicity

Mutagenicity : No known significant effects or critical hazards. **Teratogenicity** No known significant effects or critical hazards. **Developmental effects** : No known significant effects or critical hazards. **Fertility effects** : No known significant effects or critical hazards.

Numerical measures of toxicity

Acute toxicity estimates

There is no data available.

Section 12. Ecological information

Toxicity

There is no data available.

Persistence and degradability

There is no data available.

Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
Cisplatin	-2.19	-	low

Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

Other adverse effects : No known significant effects or critical hazards.



Section 13. Disposal considerations

Disposal methods

The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Care should be taken when handling empty containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Section 14. Transport information

	DOT Classification	IMDG	IATA
UN number	Not regulated.	Not regulated.	Not regulated.
UN proper shipping name	-	-	-
Transport hazard class(es)	-	-	-
Packing group	-	-	-
Environmental hazards	No.	No.	No.

AERG: Not applicable.

Special precautions for user : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Section 15. Regulatory information

Drug products are considered exempt from hazard communication labeling under the criteria of the Federal OSHA Hazard Communication Standard 29 CFR 1910.1200.

FDA

: Cisplatin is an approved prescription medication.

U.S. Federal regulations

: United States inventory (TSCA 8b): All components are listed or exempted.

Clean Water Act (CWA) 311: Hydrochloric acid; Sodium hydroxide

Clean Air Act Section 112

(b) Hazardous Air **Pollutants (HAPs)** : Listed

Clean Air Act Section 602

: Not listed

Class I Substances

Clean Air Act Section 602

: Not listed

Class II Substances

DEA List I Chemicals

: Not listed

(Precursor Chemicals)



Section 15. Regulatory information

DEA List II Chemicals (Essential Chemicals) : Not listed

SARA 302/304

Composition/information on ingredients

		SARA 302 TPQ		SARA 304 RQ	
Name	EHS	(lbs)	(gallons)	(lbs)	(gallons)
Hydrochloric acid	Yes.	500	-	5000	-

SARA 304 RQ : 5000000 lbs / 2270000 kg

SARA 311/312

Classification : CARCINOGENICITY - Category 1B

Composition/information on ingredients

Name	Classification
	ACUTE TOXICITY (oral) - Category 2 SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 1 CARCINOGENICITY - Category 1B

SARA 313

There is no data available.

State regulations

Massachusetts : None of the components are listed.

New York : The following components are listed: Cisplatin

New Jersey : None of the components are listed.

Pennsylvania : The following components are listed: Cisplatin

California Prop. 65

♠ WARNING: This product can expose you to Cisplatin, which is known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

Section 16. Other information

Procedure used to derive the classification

Classification	Justification
CARCINOGENICITY - Category 1B	Calculation method

History

Revision date mm/dd/yyyy : 12/15/2018

Version : 3

Prepared by : KMK Regulatory Services Inc.

Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.